July 8, 2022 7:59am

The sector has risen to where they've struggled; post three (3) out of five (5) July sessions

Pre-open indications:  5 Sell into Strength, 4 Negative Indications and 1 Puff/Pump/Promote

The June employment report due today

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are DOWN -0.40% or (-130 points), S&P futures are DOWN -0.79% (- 31 points) and NASDAQ futures are DOWN -1.35% (- 164 points) early in the pre-open – so far,

 

Stock futures were mixed on Friday as investors await a key jobs report,

European markets were also mixed,

Asia-Pacific markets were mostly higher.

 

Henry’omics:

Thursday, the Dow closed UP +346.87 points (+1.12%); the S&P closed UP +57.54 points (+1.50%) while the Nasdaq closed UP +259.49 points (+2.28%)

in this holiday shortened week, the Dow is up +0.92%, the S&P 500 +2% and the Nasdaq +4.4%.

Economic Data Docket: The Labor Department will release the June jobs report at 8:30 a.m. ET. Economists expect to see nonfarm payrolls rise by 270,000 vs. May's gain of 390,000 jobs. The unemployment rate is expected to hold at 3.6%. A lower jobless rate would worry the Federal Reserve, which wants to see labor markets easing. <IBD>

 

RegMed Investors’ (RMi) closing bell: “sector bounces back with some gene editors leading the charge. A pop after a down session following a holiday as a positive Friday started the month even as breath had shown signs of softening” …  https://www.regmedinvestors.com/articles/12506

Ebb and flow –

Q3/22 – 1 holiday, 1 negative and 3 positive closes

Q2/22 –

June – 1 holiday, 9 positive and 11 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes

Q1/22:

·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Sell into Strength:

Caribou Therapeutics (CRBU) closed up +$0.74 to $6.54 with a positive +$0.09 or +1.09% pre-open indication,

Fate Therapeutics (FATE) closed up +$2.30 to $30.93 with a flat $0.00 pre-open indication,

Global Blood Therapeutics (GBT) closed up +$0.93 to $34.42 with a positive +$0.34 or +0.99% pre-open indication,

Sage Therapeutics (SAGE) closed up again +$0.82 to $35.29 after Wednesday’s +$0.81 with a positive +$0.61 or +1.72% pre-open indication,

Voyager Therapeutics (VYGR) closed up +$0.49 to $6.67 with a positive +$0.21 or +3.15% pre-open indications,

 

Negative Indications:

Beam Therapeutics (BEAM) closed up +$6.11 to $51.67 after Wednesday’s -$0.93 and Tuesday’s +$6.70 with a negative -$1.35 or -2.61% pre-open indication,

Chinook Therapeutics (KDNY) closed up +$0.22 to $18.87 with a negative -$0.26 or -1.38% pre-open indication,

CRISPR Therapeutics (CRSP) closed up +$5.50 to $78.20 after Wednesday’s +$2.10 and Tuesday’s +$6.81 with a negative -$0.87 or -1.11% pre-open indication,

Intellia Therapeutics (NTLA) closed up +$3.53 to $64.04 after Wednesday’s -$2.67 and Tuesday’s +$9.17 with a negative -$1.04 or -1.62% pre-open indication,

 

Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed up +$0.23 to $6.25 with 4,771 shares traded after Wednesday’s +$1.22 to $6.02 with 14, 121 shares traded <3 mo. Average = 1,636 shares>, Tuesday’s +$0.32 to $4.80 with 496 shares traded, Monday was a holiday and last Friday’s -$0.17 to $4.48 with 568 shares.

BSTG seems to always finagling a finagle and NOTHING is CLEAN and STRAIGHTFORWARD; is it the ONLY avenue to finance to utilize non-U.S. Chinese investors?

  • WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities

 

The BOTTOM LINE: I try to keep it simple … and short!

The June employment report due today and is expected to show another month of strong hiring as the labor market bucks any signs of an impending recession or economic slowdown.

The cell and gene therapy sector is under pressure, with the major indexes still facing a lot of key resistance levels.

A sign of the times to come, Adverum Biotechnologies (ADVM), a gene therapy company will cut 78 jobs or 38% of its workforce to extend its “runway” into 2025 and focus its remaining cash on treatments for eye diseases, including a common cause of blindness. ADVM had cash, equivalents and short-term investments of $271.1 million at the end of March, said the savings will extend its cash runway one year into 2025. Following the announcement, ADVM closed up $0.17 cents to $1.40 per share, a gain of nearly 14%.

How many of my coverage list are possibly in the same position with different scientific platforms – at least five (5) – AVRO, AGTC, BLCM, SLDB, VSTM and three (3) BSTG, BLUE and MESO, those who will NEED to raise capital in this terminal capital market.

BUILD CASH POSITIONS, the upward spiral will be STRIPPED, maybe NOT all today but, it’s coming.

Monday was a holiday, Tuesday opened positive, Wednesday’s negative close following Thursday’s positive close after last Friday’s (7/1) positive close.

Be prepared, earnings or LPS (loss-per-share) sessions are on their way and many companies will be just as glad to get them out as fast-as-possible to re-set ANY trajectory in August for September.”

There is VALUE out there however, it’s about playing or betting the timing of the sector.

We are left with choosing to hang on to “our” portfolio position as it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.